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Abstract
Background: The aim of our study was to determine a potential relationship between resting 
translesional pressures ratio (Pd/Pa ratio), renal fractional fl ow reserve (rFFR) and blood 
pressure response after renal artery stenting.
Methods: Thirty fi ve hypertensive patients (49% males, mean age 64 years) with at least 
60% stenosis in angiography, underwent renal artery stenting. Translesional systolic pressure 
gradient (TSPG), Pd/Pa ratio (the ratio of mean distal to lesion and mean proximal pressures) 
and hyperemic rFFR — after intrarenal administration of papaverine — were measured befo-
re stent implantation. Ambulatory blood pressure measurements (ABPM) were recorded before 
the procedure and after 6 months. The ABPM results were presented as blood pressure changes 
in subgroups of patients with normal (≥ 0.9) vs. abnormal (< 0.9) Pd/Pa ratio and normal 
(≥ 0.8) vs. abnormal (< 0.8) rFFR.
Results: Median Pd/Pa ratio was 0.84 (interquartile range 0.79–0.91) and strongly correla-
ted with TSPG (r = –0.89, p < 0.001), minimal lumen diameter (MLD; r = 0.53, p < 0.005) 
and diameter stenosis (DS; r = –0.51, p < 0.005). Median rFFR was 0.78 (0.72–0.82). Simi-
larly, signifi cant correlation between rFFR and TSPG (r = –0.86, p < 0.0001), as well as with 
MLD (r = 0.50, p < 0.005) and DS (r = –0.51, p < 0.005) was observed. Procedural success 
was obtained in all patients. Baseline Pd/Pa ratio and rFFR did not predict hypertension re-
sponse after renal artery stenting. Median changes of 24-h systolic/diastolic blood pressure were 
comparable in patients with abnormal vs. normal Pd/Pa ratio (–4/–3 vs. 0/2 mm Hg; p = NS) 
and with abnormal vs. normal rFFR (–2/–1 vs. –2/–0.5 mm Hg, respectively).
Conclusions: Physiological assessment of renal artery stenosis using Pd/Pa ratio and papa-
verine-induced renal fractional fl ow reserve did not predict hypertension response after renal 
artery stenting. (Cardiol J 2013; 20, 4: 418–422)
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Introduction
Atherosclerotic renal artery stenosis (RAS) is 
one of the common reasons for secondary hyper-
tension [1–3] and increased risk of cardiovascular 
mortality [4, 5]. Despite excellent outcomes of 
renal artery stenting, clinical benefi t from reva-
scularization remains controversial [6]. Large 
randomized controlled trials comparing percuta-
neous angioplasty and optimal medical therapy 
did not prove revascularization advantages [7–12]. 
Thus, the identifi cation of potential predictors for 
better long-term prognosis after renal stenting 
may improve appropriate selection of subjects for 
invasive treatment. During previous years several 
studies focused on physiological assessment of 
RAS with intrarenal pressure measurements. Both 
resting pressures ratio, called “Pd/Pa ratio”, and 
hyperemic renal fractional fl ow reserve (rFFR), 
after papaverine or dopamine administration beca-
me helpful diagnostic tools [13–16]. First studies 
suggested also that translesional systolic pressure 
gradient and rFFR may predict the outcome after 
renal revascularization. The aim of our study was to 
determine a potential relationship between Pd/Pa 
ratio, rFFR and blood pressure (BP) response after 
renal artery stenting.
Methods
Study group
Out of 44 consecutive hypertensive patients 
with at least moderate unilateral RAS in noninvasi-
ve studies referred to renal angiography, 35 of them 
(49% males, mean age 64 years) with at least 60% 
stenosis in angiography, underwent renal artery 
stenting. Clinical examination was performed to 
determine demographics, duration of hypertension, 
cardiovascular risk factors, features of vascular 
disease and related comorbidities. Hypertension 
was diagnosed according to the World Health Or-
ganization (WHO) criteria (BP > 140/90 mm Hg 
or current antihypertensive treatment with at least 
2 drugs). The number of antihypertensive drugs 
and drug daily doses according to WHO criteria 
[17] were recorded at baseline and at follow-up 
visit. Blood samples for all biochemical evalua-
tions were taken after overnight fasting and after 
60 min rest in supine position. Baseline serum 
creatinine was measured before the procedure, 
estimated glomerular fitration rate (GFR) was 
calculated using the MDRD formula [18]. Patients 
with severe valvular disease, NYHA III–IV heart 
failure and GFR below 30 mL/min, history of con-
trast nephropathy or refusal to provide informed 
consent were not included.
The study was approved by the Ethics Com-
mittee and signed inform consent was obtained 
from every patient.
Renal angiography
Renal angiography was performed using stan-
dard technique via femoral approach. Anterior-
-posterior, as well as 10–20° left oblique views were 
obtained. Quantitative analysis of stenosis severity 
was performed by an operator blinded to hemo-
dynamic data. Minimal lumen diameter (MLD) 
was measured at the most tight lesion segment 
and compared to the reference lumen diameter 
(RLD) measured at the nearest normal (preferably 
proximal) artery segment. The percent diameter 
stenosis (DS) was calculated using the following 
formula: DS = 1 – (MLD/RLD) × 100 [19].
Pressure measurements
Heparin (4000–5000 U) was administered to 
maintain adequate anticoagulation during the pro-
cedure. Renal distal pressure (Pd) was obtained 
using the 0.014’’ Pressure Wire 5 (Radi Medical 
Systems, Sweden) advanced distally to the lesion, 
proximal pressure (Pa) was measured from the gu-
iding catheter tip. During pressure measurements 
tip was disengaged from the artery ostium to avoid 
pressure damping. Resting Pd/Pa ratio was calcu-
lated as the ratio of mean distal to mean proximal 
pressures. Hyperemic rFFR was calculated in the 
same way after administration of 30 mg of papa-
verine. Papaverine was diluted in non-heparinized 
saline and given selectively into renal artery via 
3 F multifunctional catheter advanced distally to the 
lesion (if possible) and quickly removed after drug 
administration. Non-ionic contrast agent and non-
heparinized saline were used to avoid papaverine 
precipitation. Mean translesional systolic pressure 
gradient (TSPG) was counted as the difference 
between proximal and distal systolic pressure. In 
one case, very tight stenosis was not crossable 
with the pressure wire and required more stiff wire 
and predilation — this patient was not included in 
the analysis.
Procedure of renal stenting was successful if 
angiographic residual stenosis less than 20% was 
obtained.
Follow-up
Before the procedure and after 6 months renal 
duplex Doppler and computed tomography (CT) 
(for potential in-stent restenosis assessment) 
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were performed. Angio-CT examinations were 
performed with a 64-detector CT scanner (So-
matom Sensation Cardiac 64; Siemens, Erlangen, 
Germany). For renal ultrasound, a HD11 (Philips, 
Eindhoven, the Netherlands) with a multiphase 
2–4-MHz convex array transducer was used. None 
signifi cant restenosis (> 50% of the vessel diame-
ter) was detected.
Ambulatory BP measurements (ABPM) were 
recorded using a SpaceLabs 90207 or 90217 (Am-
bulatory Monitoring, Redmond, Washington, USA). 
Readings were obtained every 15 min during the 
day (6:00–22:00 h) and every 30 min during the 
night (22:00–6:00 h).
ABPM were performed before the procedure 
and after 6 months. One patient did not agree to 
have a follow-up visit. Patients were encouraged 
not to change their drug regimen during the follow-
-up period.
Statistical analysis
Continuous variables are presented as median 
and interquartile range. The mean deltas were as-
sessed in Signed-Rank test and compared between 
subgroups using non-parametric Wilcoxon test with 
2-tailed p value below 0.05 considered signifi cant. 
R-Pearson correlations coeffi cient were estimated 
for categorical variables. Statistical analysis was 
performed using SAS V System ver.9.2.
Results
Characteristics of the studied group are de-
picted in Table 1.
Median Pd/Pa ratio was 0.84 (0.79–0.91) and 
strongly correlated with TSPG (r = –0.89, p < 0.001), 
MLD (r = 0.53, p < 0.005) and DS (r = –0.51, 
p < 0.005). No correlation was found between Pd/
/Pa ratio and GFR. After papaverine administra-
tion, proximal systolic pressure was reduced from 
169 (158–187) to 153 (145–169) mm Hg, distal systolic 
pressure from 124 (110–147) to 103 (85–116) mm Hg, 
resulting in the increase of TSPG from 35 (23–
–52) mm Hg to 53 (46–65) mm Hg in maximal 
hyperemia.
The median rFFR was 0.78 (0.72–0.82) 
and was not associated with GFR. Similarly, 
significant correlation between rFFR and 
TSPG (r = –0.86, p < 0.0001), as well as with 
MLD (r = 0.50, p < 0.005) and DS (r = –0.51, 
p < 0.005) was observed.
Median 15 (12–18) mm of stent length under 
pressure of 12 (10–14) atmospheres was implanted. 
The stent length moderately correlated both with 
Pd/Pa (r = –0.46, p < 0.01), and rFFR (r = –0.47, 
p < 0.01). Angiographic procedural success was 
obtained in all patients. Median Pd/Pa ratio and 
rFFR after stent implantation were: 0.98 (0.95–1) 
and 0.98 (0.94–1), respectively. Before entering 
the study, patients were treated with 4.3 (2.6–6.9) 
defi ned daily doses of 3.5 (3–5) antihypertensive 
drugs.
Neither Pd/Pa ratio nor rFFR predicted hyper-
tension response after renal stenting — the results 
of the ABPM are presented in Table 2. Only mild 
difference in daytime BP was observed between 
patients with Pd/Pa ratio below and above 0.9. 
However, it resulted from increased BP in patients 
with Pd/Pa ratio > 0.9, probably due to the changes 
Table 1. Characteristics of the studied group. 
Data presented as median with interquartile range.
Age [years] 63.0 (53–72)
Males 48.6%
Diabetes mellitus 22.7%
Smoking: present/former 5.7%/48.6%
Hypercholesterolemia 82.9%
GFR [mL/min] 69.1 (61.1–85.1)
Diameter stenosis [%] 73 (66–80)
Minimal lumen diameter 
[mm]
1.5 (1.3–2.1)
Lesion length [mm] 12.5 (9.8–13.9)
TSPG at rest [mm Hg] 35 (23–52)
TSPG at max. hyperemia 
[mm Hg]
53 (46–65)
24 h ABPM systolic/diastolic 
blood pressure:
Before procedure 136 (126–147)/
/71 (62–79)
After 6 months 135 (120–145)/
/69 (61–77)
Antihypertension treatment
before procedure/after 6 months
Number of drugs 3.5 (3–5)/3.4 (3–5)
Number of daily 
defined doses
4.3 (2.6–6.9)/
/4.1 (2.2–6.3)
Drug class taken at 
the study entry:
ACEI/ARB 82%
Beta-blocker 89%
Calcium channel blocker 73%
Diuretic 66%
Alpha-1 adrenergic blocker 25%
Other 11%
GFR — glomerular filtration rate; TSPG — translesional systolic 
pressure gradient ABPM — ambulatory blood pressure; measu-
rements ACEI — angiotensin converting enzyme inhibitor; 
ARB — angiotensin II receptor blocker
www.cardiologyjournal.org 421
Jacek Kądziela et al., Pressure measurement in renal artery stenting
in antihypertensive treatment during the follow-up 
period (–0.9 vs. 0.1 drug, p < 0.05).
Discussion
In our study, the relationship between hemo-
dynamic parameters and BP response after renal 
artery stenting was not confi rmed. Neither resting 
Pd/Pa ratio nor rFFR were related to ABPM chan-
ges after renal revascularization.
The utility of Pd/Pa ratio and rFFR as diagno-
stic tools in RAS assessment was demonstrated in 
only several trials [13–16]. Thus, the evaluation 
of its potential prognostic value in hypertension 
response after renal revascularization was urgently 
required. Previously published studies with rFFR 
or hyperemic systolic translesional gradient used 
only offi ce BP measurements as the study endpo-
int [20, 21]. Since they have obvious limitations, 
trials with 24-h ABPM were expected. Our study 
is one of the fi rst studies using ABPM in renal 
stenting evaluation in relation to hemodynamic 
measurements. First study using ABPM was 
published in December 2010 [22]. In this paper, in 
contrast to our results, the association between 
pressure gradients and BP improvement after renal 
stenting was observed. It is of note, that there are 
a few important differences between this study 
and reported by Mangiacapra et al. [22]. First of 
all, we used only papaverine bolus as hyperemic 
stimulus. 30 mg of papaverine as adequate dose 
in achieving of maximal hyperemia was previou-
sly proved [13]. Mangiacapra et al. [22] used not 
only papaverine but also dopamine in hyperemia 
inducement. And dopamine-induced, in contrast 
to papaverine-induced, mean gradient predicted 
hypertension response. Secondly, we calculated 
the baseline and hyperemic pressures ratios (called 
Pd/Pa and rFFR, respectively). In the study by 
Mangiacapra et al. [22] only mean hyperemic gra-
dient (not ratio) was related to BP improvement. 
Thirdly, we performed slightly longer follow-up 
(6 vs. 3 months). And fi nally, our group had ge-
nerally better pharmacologically controlled hy-
pertension — mean systolic pressure obtained 
from ABPM was signifi cantly lower than in the 
compared trial. That is probably the main reason 
why the overall benefi t from revascularization was 
rather modest. The results are similar to ASTRAL 
study — the ever largest trial comparing medical 
therapy and revascularization — where renal 
stenting did not provide any additional benefi t to 
standard medical therapy [11]. The ASTRAL study 
raised some doubts and criticism regarding the trial 
design — published elsewhere [23].
Limitations of the study
There are a few limitations to our study. Our 
group was relatively small — but one should take 
into account that recruitment to renal stenting 
Table 2. Results of ambulatory blood pressure (BP) measurements in relation to baseline hemodynamic 
parameters. Data presented as median with interquartile range.
Pd/Pa < 0.9 Pd/Pa ≥ 0.9 P rFFR < 0.8 rFFR ≥ 0.8 P
Systolic BP
Before intervention 137 (125–148) 135 (120–142) NS 136 (122–149) 137.5 (129–144) NS
After 6 months 135 (120–144) 136 (125–147) NS 137 (120–146) 131 (119–143) NS
p* NS NS NS NS
Change:
24 hours –4 (–14–2.5) 0 (–4–15) NS –2 (–6–13) –2 (–7–5.5) NS
Daytime –4 (–14–13.5) 9.5 (2–17) < 0.05 3 (–11–17) 4 (–4–10) NS
Night-time –1 (–14–5) –2 (–8–9) NS 1 (–14–8) –2 (–8–6) NS
Diastolic BP
Before intervention 71 (62–79) 72 (59–79) NS 72 (63–79) 70 (58–77) NS
After 6 months 68 (59–77) 74 (63–77) NS 70 (61–85) 68 (61–75) NS
p* NS NS NS NS
Change:
24 hours –3 (–6.5–2.5) 2 (–2–5) NS –1 (–5–3) –0.5 (–7.5–5) NS
Daytime –2.5 (–7.5–2.0) 3 (–2.5–10) < 0.05 1 (–4–6) 1 (–6–3) NS
Night-time –3 (–7–3) 2 (–10–8) NS –3 (–7–4) 1 (–5–3) NS
*p for difference in blood pressure between baseline and 6 months follow-up; Pd/Pa — renal artery pressures ratio (distal/proximal); 
rFFR — renal fractional flow reserve
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trials is very challenging. In ASTRAL study, the 
recruitment phase lasted 7 years and approxima-
tely 2 patients per year in each site were enrolled. 
After ASTRAL results presentation, number of 
revascularization procedures in patients with RAS 
signifi cantly decreased. Our results represent the 
experience of 1 center, with 35 patients recruited. 
For comparison, previously published trials inclu-
ded from 13 to 61 patients. Thus, the results should 
be interpreted with caution.
Our group was quite heterogeneous with wide 
range of pre-procedure ABPM, that resulted from 
recruiting all consecutive patients referred to re-
nal angioplasty. It might have had an infl uence on 
different BP response after revascularization and 
limited the value of obtained results.
Conclusions
Our study has found that physiological as-
sessment of RAS based on papaverine-induced 
hyperemia does not predict BP response after 
renal artery stenting. Despite other trials, staying 
in contrast to our results, evaluating dopamine 
induced gradients and papaverine induced ratios, 
large multicenter trials with uniform methodology 
are still needed.
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